Form 8-K Current Report
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
__________________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
report (Date of earliest event reported) June
21, 2006
Nephros,
Inc.
(Exact
Name of Registrant as Specified in Charter)
Commission
File Number: 001-32288
|
Delaware
|
|
13-3971809
|
|
(State
or other Jurisdiction of
Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
3960
Broadway, New York, New York 10032
(Address
of Principal Executive Offices)
(Zip
Code)
(212)
781-5113
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
8.01. Other Events.
On
June 21, 2006,
Nephros, Inc. held its Annual Meeting of Stockholders, at which Nephros’s
President and Chief Executive Officer, Norman J. Barta, gave an address
accompanied by
slides,
the text of which is attached hereto as Exhibit 99.1. Additionally, management
disclosed at the Annual Meeting that Nephros filed an Investigational Device
Exemption, or IDE, application with the Food and Drug Administration (“FDA”) for
its OLpūr
H2H
module
earlier this year, with respect to which it received questions from the FDA
last
week.
The information in this report shall not be deemed to be “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liability of that Section.
Item
9.01. Financial Statements and Exhibits.
(c) Exhibits
99.1 Text
of
slides accompanying Norman Barta’s address to the Annual Meeting of Stockholders
on June 21, 2006.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
June 21, 2006
NEPHROS,
INC.
By:
/s/ Norman J. Barta___________
Chief Executive Officer